RISING PHARMA HOLDINGS, INC. — Ramipril Importer Profile
Pharmaceutical Importer · #18 buyer for Ramipril · $2.0M import value · 130 shipments · UNITED STATES · DGFT Verified
RISING PHARMA HOLDINGS, INC. is the #18 importer of Ramipril from India with $2.0M in import value and 130 verified shipments. RISING PHARMA HOLDINGS, INC. holds a 1.1% market share in Ramipril imports based in UNITED STATES. The company sources from 1 verified supplier across 64 formulations shipped to 1 country. Overall, RISING PHARMA HOLDINGS, INC. imports 18 pharmaceutical products worth $87.0M across 11 therapeutic categories.
RISING PHARMA HOLDINGS, INC. — Ramipril Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Ramipril to RISING PHARMA HOLDINGS, INC.?
Verified from 130 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| AUROBINDO PHARMA LIMITED | $2.0M | 130 | 100.0% |
RISING PHARMA HOLDINGS, INC. sources Ramipril from 1 verified Indian supplier based on 130 customs records. The primary supplier is AUROBINDO PHARMA LIMITED accounting for 100.0% of imports.
Where Does RISING PHARMA HOLDINGS, INC. Import Ramipril To?
Destination countries from 130 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $2.0M | 130 | 100.0% |
RISING PHARMA HOLDINGS, INC. imports Ramipril to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $2.0M.
What Ramipril Formulations Does RISING PHARMA HOLDINGS, INC. Import?
| Formulation | Value | Shipments |
|---|---|---|
| RAMIPRIL CAPSULES 10 MG(17328X500'S)NOS | $148.1K | 3 |
| RAMIPRIL CAPSULES 5.0 MG (11520X100'S) | $116.1K | 6 |
| RAMIPRIL CAPSULES 2.5 MG (2688X500'S) | $108.4K | 6 |
| RAMIPRIL CAPSULES 2.5 MG (2880X500'S) | $96.8K | 5 |
| RAMIPRIL CAPSULES 10 MG (Ramipril capsul | $88.9K | 2 |
| RAMIPRIL CAPSULES 2.5 MG (8448X100'S) | $74.5K | 6 |
| RAMIPRIL CAPSULES 10 MG (29088X100'S)NOS | $61.1K | 3 |
| RAMIPRIL CAPSULES 10 MG (5773X500'S) | $57.3K | 3 |
| RAMIPRIL CAPSULES 10 MG (2880X500'S) | $57.1K | 2 |
| RAMIPRIL CAPSULES 2.5 MG (6864X100'S) | $50.4K | 5 |
RISING PHARMA HOLDINGS, INC. imports 64 distinct Ramipril formulations from India. The top formulation is RAMIPRIL CAPSULES 10 MG(17328X500'S)NOS with 3 shipments worth $148.1K.
Regulatory Requirements: Importing Ramipril into United States
What RISING PHARMA HOLDINGS, INC. and other importers must comply with to import Ramipril from India
Regulatory Authority
U.S. Food and Drug Administration (FDA)
Approval Process for Generic Ramipril
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
GMP Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
Import Licence & Documentation
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
Labeling & Packaging
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Ramipril from India and How Much Does RISING PHARMA HOLDINGS, INC. Import?
India exported $39.7M worth of Ramipril through 4,977 shipments from 177 suppliers to 93 countries, serving 389 buyers globally. RISING PHARMA HOLDINGS, INC. imports $2.0M of this total, accounting for 1.1% of India's Ramipril exports with 130 shipments from UNITED STATES. This is verified from 130 customs shipment records covering 64 distinct formulations.
What Is the Average Order Value for RISING PHARMA HOLDINGS, INC.'s Ramipril Imports?
RISING PHARMA HOLDINGS, INC.'s average Ramipril order value is $15.7K per consignment, based on 130 shipments totaling $2.0M. RISING PHARMA HOLDINGS, INC. is based in UNITED STATES and ranks #18 among all Ramipril importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Ramipril to RISING PHARMA HOLDINGS, INC.?
RISING PHARMA HOLDINGS, INC. sources Ramipril from 1 verified Indian supplier: AUROBINDO PHARMA LIMITED ($2.0M, 100.0%). This is based on 130 customs records.
How Does RISING PHARMA HOLDINGS, INC. Compare to Other Ramipril Importers?
RISING PHARMA HOLDINGS, INC. ranks #18 among 389 Ramipril importers from India with a 1.1% market share. The top 3 importers are WOCKHARDT UK LIMITED ($6.7M), CRESCENT PHARMA LTD ($5.8M), BROWN AND BURK UK LIMITED ($4.0M). RISING PHARMA HOLDINGS, INC. processed 130 shipments from UNITED STATES.
What Other Cardiovascular Products Does RISING PHARMA HOLDINGS, INC. Import?
RISING PHARMA HOLDINGS, INC. also imports these cardiovascular products. Each links to the detailed product page.
About RISING PHARMA HOLDINGS, INC.
RISING PHARMA HOLDINGS, INC. imports 18 products worth $87.0M. Beyond Ramipril, top products include Gabapentin, Furosemide, Ondansetron, Pioglitazone, Escitalopram. View the complete RISING PHARMA HOLDINGS, INC. profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ramipril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ramipril shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: RISING PHARMA HOLDINGS, INC. matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as RISING PHARMA HOLDINGS, INC.'s capped import value divided by total capped export value for Ramipril across all Indian exporters.
- 5.Verified Records: This page is backed by 130 individual customs records matching RISING PHARMA HOLDINGS, INC. importing Ramipril, covering 64 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 93+ countries, 389+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ramipril Import Data for RISING PHARMA HOLDINGS, INC.
Access order-level details, pricing data, supplier connections, and competitive analysis for RISING PHARMA HOLDINGS, INC.'s Ramipril imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
RISING PHARMA HOLDINGS, INC.
Full Company Profile →
18 products · $87.0M total trade · 11 categories
RISING PHARMA HOLDINGS, INC. × Ramipril
Verified from customs records
Company Overview
Top Products by RISING PHARMA HOLDINGS, INC.
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for RISING PHARMA HOLDINGS, INC..
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ramipril. For current order-level data, contact TransData Nexus.